A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model
Status:
Completed
Trial end date:
2019-10-18
Target enrollment:
Participant gender:
Summary
A randomised, Phase 2a, double-blind, placebo-controlled study to evaluate the safety,
pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-938 in
healthy subjects infected with RSV-A Memphis 37b. This study is designed to compare the
antiviral effect of EDP-938 compared to a placebo control in the respiratory syncytial virus
challenge model.